Screener
Corcept Therapeutics CORT Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Corcept Therapeutics’s reported figures.
Based on the most recent quarter.
The source filing: Corcept Therapeutics’s 10-Q, filed July 29, 2026. Open the filing →
- Filed
- Jul 29, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050613
FAQ
- What is Corcept Therapeutics's debt-to-equity?
- Corcept Therapeutics (CORT) reported debt-to-equity of 0× in Q2 2026.
- How has Corcept Therapeutics's debt-to-equity changed year-over-year?
- Corcept Therapeutics's debt-to-equity increased by 27.9% year-over-year, from 0× to 0×.
- What is the long-term trend for Corcept Therapeutics's debt-to-equity?
- Over 5 years (2020 to 2025), Corcept Therapeutics's debt-to-equity has grown at a 13.9% compound annual growth rate (CAGR), from 0× to 0×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Corcept Therapeutics's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude